Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma Helps Market Sustain Gains
Mon, 13 Apr 03:30 pm

Indian markets eroded mid-session gains on account of profit booking but later gained momentum. While BSE Sensex is trading with gains of 150 points, NSE-Nifty is trading with gains of 50 points. Almost all the sectoral indices are trading in the green, however, metal stocks and automobile stocks continue to trade in the red. Both capital goods and consumer durables have managed to sustain gains of over 1%. BSE Mid Cap and BSE Small Cap stocks are trading in the green with midcap stocks gaining about 0.3%, while smallcap stocks have gained about 1%.

Precious metals extended their losses in second half of the trading session as gold prices fell 0.3% or Rs 82, while silver prices fell 0.4% or Rs 145. Gold prices, per 10 grams, are trading at Rs 26,700 levels, while silver prices, per kilogram, traded at Rs 36,570 levels. Crude oil prices gained 2.3% or Rs 74 and are available at Rs 3,294 per barrel.

The oil & gas sector has managed to stay on the right side of the gains as Reliance Industries gained over 1%. The oil & gas major announced commissioning Purified Terephthalic (PTA) and Polyethylene Terephthalate (PET) plants at Dahej, Gujarat. The installation of PTA plants with a capacity of 1,150 kilo tones per annum (KTA) will result in increase of RIL's aggregate capacity to 3.2 million metric tonnes per annum. The PET resin plant of RIL has two lines with a combined manufacturing capacity of 650 KTA. This is the largest installation by any company at a single location. Another major, ONGC also gained over 0.5% in today's trading session.

The pharma sector attracted a lot of investors in the second half of the trading session. The sector gained over 1% in today's trading session. Shares of Suven Life Sciences gained over 3% after the company revealed that it has completed the trial run of SUVN - G3031 on healthy human volunteers. The studies is named single ascending dose (SAD). Furthermore, the company said that it has started the next trial run which is called multiple ascending dose (MAD) studies as part of Phase 1. Additionally, shares of Sun Pharma gained over 2% during the second half of the trading session.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Pharma Helps Market Sustain Gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.